MaxCyte Inc
NASDAQ:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neosperience SpA
MIL:NSP
|
IT |
|
C
|
Chongqing Hongjiu Fruit Co Ltd
HKEX:6689
|
CN |
|
P
|
Petro Usa Inc
OTC:PBAJ
|
US |
|
Val-d'Or Mining Corp
XTSX:VZZ
|
CA |
|
S
|
Strawberry Fields Reit Inc
AMEX:STRW
|
US |
|
Thomson Reuters Corp
TSX:TRI
|
CA |
MaxCyte Inc
Other Items
MaxCyte Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Other Items
$27.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Items
-$2.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-134%
|
CAGR 10-Years
-14%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Items
-$40m
|
CAGR 3-Years
67%
|
CAGR 5-Years
71%
|
CAGR 10-Years
45%
|
|
|
Waters Corp
NYSE:WAT
|
Other Items
-$39.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Items
$10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Items
-$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
See Also
What is MaxCyte Inc's Other Items?
Other Items
27.7m
USD
Based on the financial report for Dec 31, 2025, MaxCyte Inc's Other Items amounts to 27.7m USD.
What is MaxCyte Inc's Other Items growth rate?
Other Items CAGR 1Y
223%
Over the last year, the Other Items growth was 223%.
